Literature DB >> 26113652

Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR).

Scott R Evans1, Daniel Rubin2, Dean Follmann3, Gene Pennello4, W Charles Huskins5, John H Powers6, David Schoenfeld7, Christy Chuang-Stein8, Sara E Cosgrove9, Vance G Fowler10, Ebbing Lautenbach11, Henry F Chambers12.   

Abstract

Clinical trials that compare strategies to optimize antibiotic use are of critical importance but are limited by competing risks that distort outcome interpretation, complexities of noninferiority trials, large sample sizes, and inadequate evaluation of benefits and harms at the patient level. The Antibacterial Resistance Leadership Group strives to overcome these challenges through innovative trial design. Response adjusted for duration of antibiotic risk (RADAR) is a novel methodology utilizing a superiority design and a 2-step process: (1) categorizing patients into an overall clinical outcome (based on benefits and harms), and (2) ranking patients with respect to a desirability of outcome ranking (DOOR). DOORs are constructed by assigning higher ranks to patients with (1) better overall clinical outcomes and (2) shorter durations of antibiotic use for similar overall clinical outcomes. DOOR distributions are compared between antibiotic use strategies. The probability that a randomly selected patient will have a better DOOR if assigned to the new strategy is estimated. DOOR/RADAR represents a new paradigm in assessing the risks and benefits of new strategies to optimize antibiotic use.
© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  DOOR; RADAR; antibiotic use strategies

Mesh:

Substances:

Year:  2015        PMID: 26113652      PMCID: PMC4542892          DOI: 10.1093/cid/civ495

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  12 in total

1.  Scientific and ethical issues in equivalence trials.

Authors:  B Djulbegovic; M Clarke
Journal:  JAMA       Date:  2001-03-07       Impact factor: 56.272

2.  Sample size and the ethics of non-inferiority trials.

Authors:  John H Powers; Charles K Cooper; Daphne Lin; David B Ross
Journal:  Lancet       Date:  2005 Jul 2-8       Impact factor: 79.321

3.  Current issues in non-inferiority trials.

Authors:  Thomas R Fleming
Journal:  Stat Med       Date:  2008-02-10       Impact factor: 2.373

4.  Noninferiority and equivalence trials: deciphering 'similarity' of medical interventions.

Authors:  John H Powers
Journal:  Stat Med       Date:  2008-02-10       Impact factor: 2.373

Review 5.  Systematic evaluation of non-inferiority and equivalence randomized trials of anti-infective drugs.

Authors:  Yunfei Li; Yingchun He; Yucheng Sheng; Kun Wang; Jingjing Wang; Jihan Huang; Juan Yang; Qingshan Zheng
Journal:  Expert Rev Anti Infect Ther       Date:  2013-11-01       Impact factor: 5.091

6.  Evaluation of postprescription review and feedback as a method of promoting rational antimicrobial use: a multicenter intervention.

Authors:  Sara E Cosgrove; Susan K Seo; Maureen K Bolon; Kent A Sepkowitz; Michael W Climo; Daniel J Diekema; Kathleen Speck; Vidhya Gunaseelan; Gary A Noskin; Loreen A Herwaldt; Edward Wong; Trish M Perl
Journal:  Infect Control Hosp Epidemiol       Date:  2012-04       Impact factor: 3.254

Review 7.  The clinical consequences of antimicrobial resistance.

Authors:  Louis B Rice
Journal:  Curr Opin Microbiol       Date:  2009-08-27       Impact factor: 7.934

8.  Another setting for stewardship: high rate of unnecessary antimicrobial use in a veterans affairs long-term care facility.

Authors:  Emily P Peron; Amy A Hirsch; Lucy A Jury; Robin L P Jump; Curtis J Donskey
Journal:  J Am Geriatr Soc       Date:  2013-02       Impact factor: 5.562

9.  "Collateral damage" from cephalosporin or quinolone antibiotic therapy.

Authors:  David L Paterson
Journal:  Clin Infect Dis       Date:  2004-05-15       Impact factor: 9.079

Review 10.  A clinician's guide to the assessment and interpretation of noninferiority trials for novel therapies.

Authors:  Simon J W Oczkowski
Journal:  Open Med       Date:  2014-05-06
View more
  68 in total

1.  Reply to Phillips, Morris, and Walker.

Authors:  Scott Evans; Dean Follmann; David Schoenfeld; Vance G Fowler; Henry F Chambers
Journal:  Clin Infect Dis       Date:  2015-12-09       Impact factor: 9.079

2.  Desirability of outcome ranking (DOOR) for comparing diagnostic tools and early therapeutic choices in patients with suspected candidemia.

Authors:  Daniele Roberto Giacobbe; Alessio Signori; Mario Tumbarello; Riccardo Ungaro; Giovanni Sarteschi; Elisa Furfaro; Malgorzata Mikulska; Maurizio Sanguinetti; Brunella Posteraro; Angela Raffaella Losito; Gennaro De Pascale; Valerio Del Bono; Claudio Viscoli
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-11-30       Impact factor: 3.267

3.  Defining Study Outcomes That Better Reflect Individual Response to Treatment.

Authors:  Konstantia Angelidou; Paul Palumbo; Jane Lindsey; Avy Violary; Moherndran Archary; Linda Barlow; Brian Claggett; Michael Hughes; Lee-Jen Wei
Journal:  Pediatr Infect Dis J       Date:  2018-03       Impact factor: 2.129

4.  The Antibacterial Resistance Leadership Group: Progress Report and Work in Progress.

Authors:  Henry F Chip Chambers; Heather R Cross; Scott R Evans; Barry N Kreiswirth; Vance G Fowler
Journal:  Clin Infect Dis       Date:  2017-03-15       Impact factor: 9.079

Review 5.  The Role of Stewardship in Addressing Antibacterial Resistance: Stewardship and Infection Control Committee of the Antibacterial Resistance Leadership Group.

Authors:  Deverick J Anderson; Timothy C Jenkins; Scott R Evans; Anthony D Harris; Robert A Weinstein; Pranita D Tamma; Jennifer H Han; Ritu Banerjee; Robin Patel; Theoklis Zaoutis; Ebbing Lautenbach
Journal:  Clin Infect Dis       Date:  2017-03-15       Impact factor: 9.079

6.  Benefit-risk Evaluation for Diagnostics: A Framework (BED-FRAME).

Authors:  Scott R Evans; Gene Pennello; Norberto Pantoja-Galicia; Hongyu Jiang; Andrea M Hujer; Kristine M Hujer; Claudia Manca; Carol Hill; Michael R Jacobs; Liang Chen; Robin Patel; Barry N Kreiswirth; Robert A Bonomo
Journal:  Clin Infect Dis       Date:  2016-05-18       Impact factor: 9.079

Review 7.  Patient-Reported Outcome Assessments as Endpoints in Studies in Infectious Diseases.

Authors:  John H Powers; Kellee Howard; Todd Saretsky; Sarah Clifford; Steve Hoffmann; Lily Llorens; George Talbot
Journal:  Clin Infect Dis       Date:  2016-08-15       Impact factor: 9.079

8.  Random-effects meta-analysis of combined outcomes based on reconstructions of individual patient data.

Authors:  Yue Song; Feng Sun; Susan Redline; Rui Wang
Journal:  Res Synth Methods       Date:  2020-05-08       Impact factor: 5.273

9.  Using Outcomes to Analyze Patients Rather than Patients to Analyze Outcomes: A Step toward Pragmatism in Benefit:risk Evaluation.

Authors:  Scott R Evans; Dean Follmann
Journal:  Stat Biopharm Res       Date:  2016-12-06       Impact factor: 1.452

10.  Sequential, Multiple-Assignment, Randomized Trials for COMparing Personalized Antibiotic StrategieS (SMART-COMPASS).

Authors:  Scott R Evans; Dean Follmann; Ying Liu; Thomas Holland; Sarah B Doernberg; Nadine Rouphael; Toshimitsu Hamasaki; Yunyun Jiang; Judith J Lok; Thuy Tien T Tran; Anthony D Harris; Vance G Fowler; Helen Boucher; Barry N Kreiswirth; Robert A Bonomo; David Van Duin; David L Paterson; Henry Chambers
Journal:  Clin Infect Dis       Date:  2019-05-17       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.